Kalaris Therapeutics (KLRS) AI Stock Analysis

• Market Cap: $112.99M
• Dividend Yield: N/A
• Average Volume (3M): 136.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: 63.31%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 22,928,303
• 10 Day Avg. Volume: 189,046
• 30 Day Avg. Volume: 136,224
• PEG Ratio: 0.04
• Price to Book (P/B): 1.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.98
• Enterprise Value/Market Cap: 0.04
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -420.15
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: $8.81
• Price Target Upside: 3.40% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -2.14
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $5.50 ▼(-35.45% Downside)
• Action: Reiterated Date: 03/28/26
• Date: Action: Reiterated 03/28/26

The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses, and cash burn) and bearish technicals (below key moving averages with negative MACD). A constructive corporate update and cash runway visibility provide some offset, but valuation signals remain limited due to negative earnings.

Positive Factors

Strengthened balance sheet & runway

A $50M private placement and guidance showing cash runway into Q4 2027 materially reduce near-term financing pressure. That multi-year runway allows management to plan and advance TH103 into later-stage trials without immediate dilution risk, supporting execution over the next 2–6 months.

Negative Factors

No revenue / persistent losses

Absence of product revenue means the company cannot self-fund development; performance depends on capital markets or partners. Persistent operating losses keep profitability distant and make operating plans contingent on external funding rather than internal cash generation over the medium term.

Kalaris Therapeutics Business Overview & Revenue Model

Company Description

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severe...

Read more

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severe...

How the Company Makes Money

As a clinical-stage biotechnology company, Kalaris Therapeutics does not have a recurring product-revenue business model. Its funding has historically been expected to come primarily from financing activities (such as selling equity and, where app...

Read more

As a clinical-stage biotechnology company, Kalaris Therapeutics does not have a recurring product-revenue business model. Its funding has historically been expected to come primarily from financing activities (such as selling equity and, where app...

Kalaris Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-13.00K	0.00	0.00	0.00	-1.12M
EBITDA	-46.14M	-58.77M	-14.01M	-15.25M	-169.84M
Net Income	-43.44M	-58.77M	-14.70M	-15.48M	-171.96M
Balance Sheet
Total Assets	121.74M	118.55M	3.33M	3.90M	286.59M
Cash, Cash Equivalents and Short-Term Investments	117.98M	118.29M	3.17M	3.06M	248.12M
Total Debt	1.45M	0.00	0.00	3.25M	30.07M
Total Liabilities	42.92M	5.24M	48.35M	34.17M	61.33M
Stockholders Equity	78.81M	113.31M	-45.02M	-30.27M	225.27M
Cash Flow
Free Cash Flow	-43.18M	-67.70M	-14.13M	-9.78M	-106.34M
Operating Cash Flow	-42.98M	-67.70M	-14.13M	-9.78M	-106.32M
Investing Cash Flow	-19.72M	95.00M	0.00	0.00	185.98M
Financing Cash Flow	159.61M	21.00K	14.24M	12.78M	232.00K

Kalaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLRS, the sentiment is Negative. The current price of 8.52 is above the 20-day moving average (MA) of 8.19, below the 50-day MA of 9.03, and above the 200-day MA of 5.92, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 22.83 is Positive, neither overbought nor oversold. The STOCH value of 4.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KLRS.

Kalaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NKTR	57 Neutral	$1.97B	―	-399.10%	―	-32.79%	36.87%
KOD	54 Neutral	$2.26B	-3.52	-246.19%	―	―	-12.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CHRS	51 Neutral	$244.32M	-1.00	789.35%	―	-72.54%	-19972.15%
KLRS	45 Neutral	$112.99M	-2.97	-73.11%	―	―	63.31%
CLLS	45 Neutral	$234.65M	-7.16	-69.63%	―	158.54%	66.90%
MCRB	43 Neutral	$86.28M	-2.15	13.30%	―	448.44%	―

Kalaris Therapeutics Corporate Events